These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 649984)

  • 1. Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition.
    Wick MM; Kramer RA; Gorman M
    J Invest Dermatol; 1978 Jun; 70(6):358-60. PubMed ID: 649984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment effects on the uptake/retention kinetics of L-dopa in Harding-Passey melanoma.
    Berjian RA; Kanter PM; Bhakoo HS; Tan MH; Lawrence DD
    J Invest Dermatol; 1986 May; 86(5):560-2. PubMed ID: 3745966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective incorporation of L-3,4-dihydroxyphenylalanine by S-91 Cloudman melanoma in vitro.
    Wick MM; Frei E
    Cancer Res; 1977 Jul; 37(7 Pt 1):2123-5. PubMed ID: 861938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in melanin formation and promotion of cytotoxicity in cultured melanoma cells caused by phosphorylated isomers of L-dopa.
    Pawelek JM; Murray M
    Cancer Res; 1986 Feb; 46(2):493-7. PubMed ID: 3079662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [EFFECT OF THE DOPA-DECARBOXYLASE INHIBITOR ALPHA-METHYLDOPA ON THE INCORPORATION OF DOPA INTO MELANIN AND PYROCATECHOLAMINE. IN VIVO STUDIES ON MELANOMA MICE WITH TRITIATED DOPA].
    HEMPEL K; DEIMEL M
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1963 Nov; 246():203-14. PubMed ID: 14095447
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 8. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apical and basolateral uptake and intracellular fate of dopamine precursor L-dopa in LLC-PK1 cells.
    Soares-Da-Silva P; Serrão MP; Vieira-Coelho MA
    Am J Physiol; 1998 Feb; 274(2):F243-51. PubMed ID: 9486218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes.
    Musso NR; Brenci S; Setti M; Indiveri F; Lotti G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3553-7. PubMed ID: 8855800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopamine agonists and antagonists on murine melanoma: correlation with dopamine binding activity.
    Krummel TM; Neifeld JP; Taub RN
    Cancer; 1982 Mar; 49(6):1178-84. PubMed ID: 7059943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-Dopa methyl ester: prolongation of survival of neuroblastoma-bearing mice after treatment.
    Wick MM
    Science; 1978 Feb; 199(4330):775-6. PubMed ID: 622565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
    Lindén IB; Neuvonen PJ; Vapaatalo H
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alpha-MSH on the tyrosinase activity and the rate of melanin accumulation of melanoma cells in vitro.
    Lee TH; Lee MS
    Acta Endocrinol (Copenh); 1977 Mar; 84(3):663-72. PubMed ID: 402759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoacids--precursors of melanin synthesis in hamster melanoma.
    Blagoeva PM
    J Cancer Res Clin Oncol; 1984; 108(3):366-8. PubMed ID: 6511810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells.
    Kable EP; Parsons PG
    Cancer Chemother Pharmacol; 1989; 23(1):1-7. PubMed ID: 2909284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.